{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T18:16:31Z","timestamp":1788113791150,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>Achromobacter<\/jats:italic> spp. are opportunistic pathogens, mostly infecting immunocompromised patients and patients with cystic fibrosis (CF) and considered as difficult-to-treat pathogens due to both intrinsic resistance and the possibility of acquired antimicrobial resistance. Species identification remains challenging leading to imprecise descriptions of resistance in each taxon. Cefiderocol is a broad-spectrum siderophore cephalosporin increasingly used in the management of <jats:italic>Achromobacter<\/jats:italic> infections for which susceptibility data remain scarce. We aimed to describe the susceptibility to cefiderocol of a collection of <jats:italic>Achromobacter<\/jats:italic> strains encompassing different species and isolation sources from CF or non-CF (NCF) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We studied 230 <jats:italic>Achromobacter<\/jats:italic> strains (67 from CF, 163 from NCF patients) identified by <jats:italic>nrdA<\/jats:italic> gene-based analysis, with available susceptibility data for piperacillin\u2013tazobactam, meropenem and trimethoprim\u2013sulfamethoxazole. Minimal inhibitory concentrations (MICs) of cefiderocol were determined using the broth microdilution reference method according to EUCAST guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Strains belonged to 15 species. <jats:italic>A. xylosoxidans<\/jats:italic> represented the main species (71.3%). MICs ranged from \u2264\u20090.015 to 16\u00a0mg\/L with MIC<jats:sub>50\/90<\/jats:sub> of \u2264\u20090.015\/0.5\u00a0mg\/L overall and 0.125\/2\u00a0mg\/L against 27 (11.7%) meropenem-non-susceptible strains. Cefiderocol MICs were not related to CF\/NCF origin or species although <jats:italic>A. xylosoxidans<\/jats:italic> MICs were statistically lower than those of other species considered as a whole. Considering the EUCAST non-species related breakpoint (2\u00a0mg\/L), 228 strains (99.1%) were susceptible to cefiderocol. The two cefiderocol-resistant strains (<jats:italic>A. xylosoxidans<\/jats:italic> from CF patients) represented 3.7% of meropenem-non-susceptible strains and 12.5% of MDR strains.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Cefiderocol exhibited excellent in vitro activity against a large collection of accurately identified <jats:italic>Achromobacter<\/jats:italic> strains, irrespective of species and origin.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12941-024-00709-z","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T15:01:57Z","timestamp":1718636517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains"],"prefix":"10.1186","volume":"23","author":[{"given":"Vincent","family":"Jean-Pierre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Sorlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Chiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Lavigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Jeannot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Marchandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Collaborative study group on antimicrobial resistance of Achromobacter spp.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marl\u00e8ne","family":"Amara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Cadot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dauwalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Degand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Demar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Dupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Sarah","family":"Fangous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Franczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Guiet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Guinard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Hombrouck-Alet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atika","family":"Kaoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mariani-Kurkdjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"N\u00f8rskov-Lauritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Tellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Texier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Violette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"709_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.1971.tb00607.x","author":"E Yabuuchi","year":"1971","unstructured":"Yabuuchi E, Ohyama A. Achromobacter xylosoxidans n. sp. from human ear discharge. Jpn J Microbiol. 1971. https:\/\/doi.org\/10.1111\/j.1348-0421.1971.tb00607.x.","journal-title":"Jpn J Microbiol"},{"key":"709_CR2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.02293-13","author":"L Amoureux","year":"2013","unstructured":"Amoureux L, Bador J, Fardeheb S, Mabille C, Couchot C, Massip C, et al. Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates. Appl Environ Microbiol. 2013. https:\/\/doi.org\/10.1128\/AEM.02293-13.","journal-title":"Appl Environ Microbiol"},{"key":"709_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2014.07.012","author":"E Hugon","year":"2015","unstructured":"Hugon E, Marchandin H, Poir\u00e9e M, Fosse T, Sirvent N. Achromobacter bacteraemia outbreak in a paediatric onco-haematology department related to strain with high surviving ability in contaminated disinfectant atomizers. J Hosp Infect. 2015. https:\/\/doi.org\/10.1016\/j.jhin.2014.07.012.","journal-title":"J Hosp Infect"},{"key":"709_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.10.002","author":"T Spilker","year":"2013","unstructured":"Spilker T, Vandamme P, LiPuma JJ. Identification and distribution of Achromobacter species in cystic fibrosis. J Cyst Fibros. 2013. https:\/\/doi.org\/10.1016\/j.jcf.2012.10.002.","journal-title":"J Cyst Fibros"},{"key":"709_CR5","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00814-12","author":"T Spilker","year":"2012","unstructured":"Spilker T, Vandamme P, LiPuma JJ. A multilocus sequence typing scheme implies population structure and reveals several putative novel Achromobacter species. J Clin Microbiol. 2012. https:\/\/doi.org\/10.1128\/JCM.00814-12.","journal-title":"J Clin Microbiol"},{"key":"709_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02953-23","author":"P Sorlin","year":"2024","unstructured":"Sorlin P, Brivet E, Jean-Pierre V, Aujoulat F, Besse A, Dupont C, et al. Prevalence and variability of siderophore production in the Achromobacter genus. Microbiol Spectr. 2024. https:\/\/doi.org\/10.1128\/spectrum.02953-23.","journal-title":"Microbiol Spectr"},{"key":"709_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.12.009","author":"L Amoureux","year":"2016","unstructured":"Amoureux L, Bador J, Bounoua Zouak F, Chapuis A, De Curraize C, Neuwirth C. Distribution of the species of Achromobacter in a French cystic fibrosis centre and multilocus sequence typing analysis reveal the predominance of A. xylosoxidans and clonal relationships between some clinical and environmental isolates. J Cyst Fibros. 2016. https:\/\/doi.org\/10.1016\/j.jcf.2015.12.009.","journal-title":"J Cyst Fibros"},{"key":"709_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.02422-21","author":"T Garrigos","year":"2022","unstructured":"Garrigos T, Dollat M, Magallon A, Folletet A, Bador J, Abid M, et al. Distribution of Achromobacter species in 12 French cystic fibrosis centers in 2020 by a retrospective MALDI-TOF MS spectrum analysis analysis. J Clin Microbiol. 2022. https:\/\/doi.org\/10.1128\/jcm.02422-21.","journal-title":"J Clin Microbiol"},{"key":"709_CR9","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268816001564","author":"L Amoureux","year":"2016","unstructured":"Amoureux L, Bador J, Verrier T, Mjahed H, De Curraize C, Neuwirth C. Achromobacter xylosoxidans is the predominant Achromobacter species isolated from diverse non-respiratory samples. Epidemiol Infect. 2016. https:\/\/doi.org\/10.1017\/S0950268816001564.","journal-title":"Epidemiol Infect"},{"key":"709_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00494-13","author":"L Barrado","year":"2013","unstructured":"Barrado L, Bra\u00f1as P, Orellana M\u00c1, Mart\u00ednez MT, Garc\u00eda G, Otero JR, et al. Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid. Spain J Clin Microbiol. 2013. https:\/\/doi.org\/10.1128\/JCM.00494-13.","journal-title":"Spain J Clin Microbiol"},{"key":"709_CR11","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters Version 13.1; 2023. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_13.1_Breakpoint_Tables.pdf. Accessed 10 Mar 2024."},{"key":"709_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.08.015","author":"M Almuzara","year":"2010","unstructured":"Almuzara M, Limansky A, Ballerini V, Galanternik L, Famiglietti A, Vay C. In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods. Int J Antimicrob Agents. 2010. https:\/\/doi.org\/10.1016\/j.ijantimicag.2009.08.015.","journal-title":"Int J Antimicrob Agents"},{"key":"709_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x","author":"A-P Magiorakos","year":"2012","unstructured":"Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x.","journal-title":"Clin Microbiol Infect"},{"key":"709_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01025-20","author":"B Isler","year":"2020","unstructured":"Isler B, Kidd TJ, Stewart AG, Harris P, Paterson DL. Achromobacter infections and treatment options. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/AAC.01025-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"709_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1055-2","author":"GG Zhanel","year":"2019","unstructured":"Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli. Drugs. 2019. https:\/\/doi.org\/10.1007\/s40265-019-1055-2.","journal-title":"Drugs"},{"key":"709_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv402","author":"A Ito","year":"2016","unstructured":"Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother. 2016. https:\/\/doi.org\/10.1093\/jac\/dkv402.","journal-title":"J Antimicrob Chemother"},{"key":"709_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-017-3063-z","author":"J Dobias","year":"2017","unstructured":"Dobias J, D\u00e9nervaud-Tendon V, Poirel L, Nordmann P. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017. https:\/\/doi.org\/10.1007\/s10096-017-3063-z.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"709_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01405-16","author":"A Ito","year":"2016","unstructured":"Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016. https:\/\/doi.org\/10.1128\/AAC.01405-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"709_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01454-17","author":"A Ito","year":"2018","unstructured":"Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.01454-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"709_CR20","doi-asserted-by":"publisher","DOI":"10.52586\/5054","author":"S Esposito","year":"2021","unstructured":"Esposito S, Pisi G, Fainardi V, Principi N. What is the role of Achromobacter species in patients with cystic fibrosis? Front Biosci. 2021. https:\/\/doi.org\/10.52586\/5054.","journal-title":"Front Biosci"},{"key":"709_CR21","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2020.0602","author":"EM Gavioli","year":"2021","unstructured":"Gavioli EM, Guardado N, Haniff F, Deiab N, Vider E. Does cefiderocol have a potential role in cystic fibrosis pulmonary exacerbation management? Microb Drug Resist. 2021. https:\/\/doi.org\/10.1089\/mdr.2020.0602.","journal-title":"Microb Drug Resist"},{"key":"709_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24945","author":"AB Gainey","year":"2020","unstructured":"Gainey AB, Burch A, Brownstein MJ, Brown DE, Fackler J, Horne B, et al. Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr Pulmonol. 2020. https:\/\/doi.org\/10.1002\/ppul.24945.","journal-title":"Pediatr Pulmonol"},{"key":"709_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25552","author":"R Belcher","year":"2021","unstructured":"Belcher R, Zobell JT. Optimization of antibiotics for cystic fibrosis pulmonary exacerbations due to highly resistant nonlactose fermenting Gram negative bacilli: meropenem-vaborbactam and cefiderocol. Pediatr Pulmonol. 2021. https:\/\/doi.org\/10.1002\/ppul.25552.","journal-title":"Pediatr Pulmonol"},{"key":"709_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00385-4","author":"M Bodro","year":"2021","unstructured":"Bodro M, Hern\u00e1ndez-Meneses M, Ambrosioni J, Linares L, Moreno A, Sandoval E, et al. Salvage treatment with cefiderocol regimens in two intravascular foreign body infections by MDR Gram-negative pathogens, involving non-removable devices. Infect Dis Ther. 2021. https:\/\/doi.org\/10.1007\/s40121-020-00385-4.","journal-title":"Infect Dis Ther"},{"key":"709_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02171-20","author":"EK McCreary","year":"2021","unstructured":"McCreary EK, Heil EL, Tamma PD. New perspectives on antimicrobial agents: cefiderocol. Antimicrob Agents Chemother. 2021. https:\/\/doi.org\/10.1128\/AAC.02171-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"709_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1847","author":"NC Warner","year":"2021","unstructured":"Warner NC, Bartelt LA, Lachiewicz AM, Tompkins KM, Miller MB, Alby K, et al. Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and Achromobacter xylosoxidans infections. Clin Infect Dis. 2021. https:\/\/doi.org\/10.1093\/cid\/ciaa1847.","journal-title":"Clin Infect Dis"},{"key":"709_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11121686","author":"G La Bella","year":"2022","unstructured":"La Bella G, Salvato F, Minafra GA, Bottalico IF, Rollo T, Barbera L, et al. Successful treatment of aortic endocarditis by Achromobacter xylosoxidans with cefiderocol combination therapy in a non-Hodgkin lymphoma patient: case report and literature review. Antibiotics. 2022. https:\/\/doi.org\/10.3390\/antibiotics11121686.","journal-title":"Antibiotics"},{"key":"709_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00776-3","author":"\u00c1M Fendian","year":"2023","unstructured":"Fendian \u00c1M, Albanell-Fern\u00e1ndez M, Tuset M, Pitart C, Castro P, Soy D, et al. Real-life data on the effectiveness and safety of cefiderocol in severely infected patients: a case series. Infect Dis Ther. 2023. https:\/\/doi.org\/10.1007\/s40121-023-00776-3.","journal-title":"Infect Dis Ther"},{"key":"709_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-023-01146-5","author":"P Viale","year":"2023","unstructured":"Viale P, Sandrock CE, Ramirez P, Rossolini GM, Lodise TP. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence. Ann Intensive Care. 2023. https:\/\/doi.org\/10.1186\/s13613-023-01146-5.","journal-title":"Ann Intensive Care"},{"key":"709_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.12.021","author":"L Devoos","year":"2023","unstructured":"Devoos L, Biguenet A, Rousselot J, Bour M, Pl\u00e9siat P, Fournier D, et al. Performance of discs, sensititre EUMDROXF microplates and MTS gradient strips for the determination of the susceptibility of multidrug-resistant Pseudomonas aeruginosa to cefiderocol. Clin Microbiol Infect. 2023. https:\/\/doi.org\/10.1016\/j.cmi.2022.12.021.","journal-title":"Clin Microbiol Infect"},{"key":"709_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.03.003","author":"MA Hackel","year":"2019","unstructured":"Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth. Diagn Microbiol Infect Dis. 2019. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.03.003.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"709_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9122473","author":"C Beauruelle","year":"2021","unstructured":"Beauruelle C, Lamoureux C, Mashi A, Ramel S, Le Bihan J, Ropars T, et al. In vitro activity of 22 antibiotics against Achromobacter isolates from people with cystic fibrosis. Are there new therapeutic options? Microorganisms. 2021. https:\/\/doi.org\/10.3390\/microorganisms9122473.","journal-title":"Microorganisms"},{"key":"709_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01649-20","author":"CP Morris","year":"2020","unstructured":"Morris CP, Bergman Y, Tekle T, Fissel JA, Tamma PD, Simner PJ. Cefiderocol antimicrobial susceptibility testing against multidrug-resistant Gram-negative bacilli: a comparison of disk diffusion to broth microdilution. J Clin Microbiol. 2020. https:\/\/doi.org\/10.1128\/JCM.01649-20.","journal-title":"J Clin Microbiol"},{"key":"709_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11101352","author":"S Oueslati","year":"2022","unstructured":"Oueslati S, Bogaerts P, Dortet L, Bernabeu S, Ben Lakhal H, Longshaw C, et al. In vitro activity of cefiderocol and comparators against carbapenem-resistant Gram-negative pathogens from France and Belgium. Antibiotics. 2022. https:\/\/doi.org\/10.3390\/antibiotics11101352.","journal-title":"Antibiotics"},{"key":"709_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01955-19","author":"KVI Rolston","year":"2020","unstructured":"Rolston KVI, Gerges B, Shelburne S, Aitken SL, Raad I, Prince RA. Activity of cefiderocol and comparators against isolates from cancer patients. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/AAC.01955-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"709_CR36","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00346-23","author":"M Takemura","year":"2023","unstructured":"Takemura M, Nakamura R, Ota M, Nakai R, Sahm DF, Hackel MA, et al. In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. Antimicrob Agents Chemother. 2023. https:\/\/doi.org\/10.1128\/aac.00346-23.","journal-title":"Antimicrob Agents Chemother"},{"key":"709_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12040785","author":"M Padovani","year":"2023","unstructured":"Padovani M, Bertelli A, Corbellini S, Piccinelli G, Gurrieri F, De Francesco MA. In vitro activity of cefiderocol on multiresistant bacterial strains and genomic analysis of two cefiderocol resistant strains. Antibiotics. 2023. https:\/\/doi.org\/10.3390\/antibiotics12040785.","journal-title":"Antibiotics"},{"key":"709_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-024-04745-7","author":"G Bianco","year":"2024","unstructured":"Bianco G, Boattini M, Comini S, Gaibani P, Cavallo R, Costa C. Performance evaluation of Bruker UMIC\u00ae microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species. Eur J Clin Microbiol Infect Dis. 2024. https:\/\/doi.org\/10.1007\/s10096-024-04745-7.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"709_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2024.01.023","author":"MM Tunney","year":"2024","unstructured":"Tunney MM, Elborn JS, McLaughlin CS, Longshaw CM. In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis. J Glob Antimicrob Resist. 2024. https:\/\/doi.org\/10.1016\/j.jgar.2024.01.023.","journal-title":"J Glob Antimicrob Resist"},{"key":"709_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.08.029","author":"S Karakonstantis","year":"2024","unstructured":"Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis EI. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. Clin Microbiol Infect. 2024. https:\/\/doi.org\/10.1016\/j.cmi.2023.08.029.","journal-title":"Clin Microbiol Infect"},{"key":"709_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00951-20","author":"PJ Simner","year":"2020","unstructured":"Simner PJ, Patel R. Cefiderocol antimicrobial susceptibility testing considerations: the Achilles\u2019 heel of the Trojan horse? J Clin Microbiol. 2020. https:\/\/doi.org\/10.1128\/JCM.00951-20.","journal-title":"J Clin Microbiol"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-024-00709-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-024-00709-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-024-00709-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T15:02:12Z","timestamp":1718636532000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-024-00709-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1186\/s12941-024-00709-z","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"10 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}